This trial assessed the addition of chemotherapy to Stage I (deeply invasive) grade 3 endometrial cancer and demonstrated improvement in failure free survival though no improvement in overall survival. This trial demonstrates that current practice patterns of EBRT alone for these patients is sufficient given additional toxicities associated with chemotherapy. Currently standard of care remains EBRT alone for this cohort of patients.

PDF

Journal & Date: Lancet Oncology, Volume 19, No. 3, p295–309, March 2018
Key Institution:  International, multicenter
Keywords: Endometrial cancer, Radiotherapy, Chemotherapy, Clinical Trial